CANLAB RESEARCH
⚠️ High Risk
FEI: 3017270789 • Laval, QC • CANADA
FEI Number
3017270789
Location
Laval, QC
Country
CANADAAddress
1555 Boul De Lavenir Su, , Laval, QC, Canada
High Risk
FDA Import Risk Assessment
This firm has a significant history of FDA import refusals with notable violations.
Statistics
Score Breakdown
How is this score calculated?
Proprietary Algorithm
- 40% Violation Severity — AI-assessed (1-10)
- 30% Refusal Volume — Logarithmic scale
- 20% Recency — Decays over 5 years
- 10% Frequency — Refusals per year
© ImportRefusal.com Original Analysis
Violation Summary
UNAPPROVED
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).
NOT LISTED
It appears the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by section 510(j) or 510(k).
FRNMFGREG
The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. It appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act.
LACKS FIRM
The article is subject to refusal of admission pursuant to Section 801(a)(3) of the FD&C Act in that it appears to be misbranded within the meaning of Section 403(e)(1) of the FD&C Act in that the food is in package form and the label fails to bear the name and place of business of the manufacturer, packer, or distributor.
LACKS FIRM
The article is in package form and appears to not bear a label containing the name and place of business of the manufacturer, packer, or distributor.
DIETARYING
The article is subject to refusal of admission pursuant to Section 801(a)(3) of the FD&C Act in that it is a dietary supplement that appears to be misbranded within the meaning of Section 403(s)(2)(A) of the FD&C Act in that the dietary supplement label or labeling fails to list the name of each dietary ingredient of the supplement and the quantity of each such dietary ingredient or , with respect to a proprietary blend of such dietary ingredients, the total quantity of all dietary ingredients in the blend.
NCONTACT
The article is subject to refusal of admission pursuant to Section 801(a)(3) of the FD&C Act in that it is a dietary supplement that appears to be misbranded within the meaning of Section 403(y) of the FD&C Act in that the dietary supplement label fails to bear a domestic address or phone number through which the responsible person (as described in section 761 of the FD&C Act) may receive a report of a serious adverse event with such dietary supplement.
NO 510(K)
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it is a post 1976 device for which a Section 510(k)application does not appear to have been determined substantially equivalent or otherwise filed.
DIETARYLBL
The article is subject to refusal of admission pursuant to Section 801(a)(3) of the FD&C Act in that it is a dietary supplement that appears to be misbranded within the meaning of Section 403(s)(2)(B) of the FD&C Act in that the label or labeling fails to identify the product by using the term "dietary supplement", which term may be modified with the name of such an ingredient.
DIRSEXMPT
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use.
Refusal History
| Date | Product | Violations | Division |
|---|---|---|---|
| 7/20/2022 | 88PPMGENERAL PURPOSE REAGENT | Division of Southeast Imports (DSEI) | |
| 7/7/2022 | 56FYY99PEPTIDE N.E.C. | Division of Southeast Imports (DSEI) | |
| 6/30/2022 | 75NBCTEST, NATRIURETIC PEPTIDE | 508NO 510(K) | Division of Southeast Imports (DSEI) |
| 6/30/2022 | 57VL99IN-VITRO DIAG PRODUCTS, N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 6/30/2022 | 56FYY99PEPTIDE N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 6/23/2022 | 66VDZ99MISCELLANEOUS PATENT MEDICINES, ETC. | Division of Southeast Imports (DSEI) | |
| 6/17/2022 | 66VIY99MISCELLANEOUS PATENT MEDICINES, ETC. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 6/10/2022 | 56FIY99PEPTIDE N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 6/6/2022 | 56FIZ99PEPTIDE N.E.C. | Division of Southeast Imports (DSEI) | |
| 6/2/2022 | 56FYY99PEPTIDE N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 12/29/2021 | 56FAY99PEPTIDE N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 12/13/2021 | 56FAY99PEPTIDE N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 9/23/2021 | 65FIY05WATER, FOR INJECTION, BACTERIOSTATIC, U.S.P. (PHARMACEUTIC AID) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 9/23/2021 | 56FIY99PEPTIDE N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 9/17/2021 | 56FDY99PEPTIDE N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 9/17/2021 | 56FDY99PEPTIDE N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 9/17/2021 | 56FDY99PEPTIDE N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 9/17/2021 | 56FDY99PEPTIDE N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 9/17/2021 | 56FDY99PEPTIDE N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 9/17/2021 | 56FDY99PEPTIDE N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 9/17/2021 | 56FDY99PEPTIDE N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 7/26/2021 | 56FIY99PEPTIDE N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 7/26/2021 | 56YIY99ANTIBIOTIC N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 2/26/2021 | 56FIY99PEPTIDE N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 2/26/2021 | 56FIY99PEPTIDE N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 1/6/2021 | 56FIT99PEPTIDE N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 10/19/2020 | 54FYL99HERBALS & BOTANICALS (NOT TEAS), N.E.C. | Division of Southeast Imports (DSEI) |
Frequently Asked Questions
What is CANLAB RESEARCH's FDA import refusal history?
CANLAB RESEARCH (FEI: 3017270789) has 27 FDA import refusal record(s) in our database, spanning from 10/19/2020 to 7/20/2022.
What is an FEI number?
FEI stands for Firm Establishment Identifier. It's a unique number assigned by the FDA to identify establishments that manufacture, process, pack, or hold food, drugs, medical devices, or other FDA-regulated products. CANLAB RESEARCH's FEI number is 3017270789.
What types of violations has CANLAB RESEARCH received?
CANLAB RESEARCH has been cited for 10 different violation type(s). Common FDA violations include adulteration (unsafe or unsanitary products), misbranding (incorrect or misleading labels), and regulatory non-compliance.
Where does this information about CANLAB RESEARCH come from?
All FDA import refusal data for CANLAB RESEARCH is sourced from the official FDA Data Dashboard (datadashboard.fda.gov), a public government database maintained by the U.S. Food and Drug Administration.
Data sourced from the FDA Data Dashboard, a public database maintained by the U.S. Food and Drug Administration.